Theramex announces agreement to acquire the european rights to duphaston® and femoston® from viatris, inc.

London--(business wire)--theramex, a leading global speciality pharmaceutical company dedicated to women's health, is pleased to announce that it has entered into an agreement to acquire the european rights to duphaston® and femoston® from viatris inc. viatris retains the rights for australia and japan. the transaction is subject to customary regulatory and anti-trust approvals. “as we continue to strengthen our commitment to women's health and improve our patients access to high quality treatm.
VTRS Ratings Summary
VTRS Quant Ranking